Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9031281 | 0.95 | HSD17B3 (0.54) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL11990926 | 0.89 | SLC6A2 (0.55) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL11781795 | 0.84 | CES2 (0.49) | SLC6A2SLC6A3LMNAMAPK1NPC1 | |
| SCHEMBL28728629 | 0.82 | HSD17B3 (0.53) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL28376164 | 0.81 | LMNA (0.56) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL27527322 | 0.81 | HSD17B3 (0.51) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL10711276 | 0.80 | THRA (0.56) | ALDH1A1 | |
| SCHEMBL637814 | 0.79 | GPR84 (0.53) | SLC6A2SLC6A3LMNAGPR84 | |
| SCHEMBL8577344 | 0.78 | LMNA (0.54) | HSD17B3SLC6A2SLC6A3ESR1LMNA | |
| SCHEMBL6936418 | 0.78 | CYP4A11 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103724269-A | Phenyl 1, 2-isoxazole or phenyl 1, 2-pyrazole compound and application thereof | SHANGHAI INST MATERIA MEDICA | 2014-04-16 | — | — | CN | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| EP-1366012-A4 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
| EP-0904079-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0882029-B1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0904079-A4 | — | — | 1999-05-06 | — | — | EP | disclosed |
| EP-0904079-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5859051-A | ACETYLPHENOL DERIVATIVES | MERCK & CO., INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997027857-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028149-A1 | METHOD FOR RAISING HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | HSD17B3 319/4885SLC6A2 3669/4885SLC6A3 2479/4885 |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | HSD17B3 297/4885SLC6A2 4317/4885SLC6A3 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.